Compare Moody's Corporation (MCO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs GeneDx Holdings Corp — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Moody's Corporation is far larger — about 39.3× GeneDx Holdings Corp's market cap, and Moody's Corporation pays a 0.9% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and GeneDx Holdings Corp for 19 Days on average.
| MCO | WGS | |
|---|---|---|
Market Cap | $79.44B | $2.02B |
Volume | 526,684 | 734,640 |
Sector | Financials | Health |
52-Week High | $539.61 | $167.51 |
52-Week Low | $412.23 | $34.51 |
Typical Hold Time | 132 Days | 19 Days |
Enterprise Value | $85.46B | $2.05B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals. Revenue grew to $7.72B in 2025, with net income margin expanding to 34.25%. Recent news highlights Moody's top RiskTech100 ranking and expansion into Asia-Pacific via a PhilRatings stake. The stock faces resistance near $461, with support at $454.
Outlook remains positive given consistent earnings beats, high profitability, and a $536.40 analyst price target implying 17% upside. Risks include high valuation multiples and macroeconomic sensitivity. Institutional sentiment is bullish with 56% buy ratings, though technical indicators suggest near-term caution.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
